Expression and clinical significance of cytochrome b561 in endometrial cancer.
To investigate the expression level of cytochrome b561 (CYB561) in endometrial carcinoma tissues and analyze its relationship with clinicopathological characteristics and patient prognosis.
Bioinformatic analysis was performed to assess CYB561 mRNA expression and its correlation with prognosis in endometrial cancer. Immunohistochemical staining was used to detect CYB561 protein expression in 195 endometrial carcinoma tissues and 40 adjacent normal endometrial tissues. The associations between CYB561 expression and clinicopathological parameters, as well as its impact on overall survival (OS) and disease-free survival (DFS), were analyzed.
CYB561 expression was significantly higher in endometrial carcinoma tissues compared to adjacent normal tissues (P < 0.001). Low CYB561 expression was significantly associated with advanced FIGO stage (P < 0.05). Moreover, patients with low CYB561 expression exhibited significantly poorer overall survival (OS) and disease-free survival (DFS) (log-rank P < 0.001 for both).
CYB561 is up-regulated in endometrial carcinoma, and its high expression is associated with a more favorable prognosis, suggesting its potential role as a prognostic biomarker for endometrial cancer.
Bioinformatic analysis was performed to assess CYB561 mRNA expression and its correlation with prognosis in endometrial cancer. Immunohistochemical staining was used to detect CYB561 protein expression in 195 endometrial carcinoma tissues and 40 adjacent normal endometrial tissues. The associations between CYB561 expression and clinicopathological parameters, as well as its impact on overall survival (OS) and disease-free survival (DFS), were analyzed.
CYB561 expression was significantly higher in endometrial carcinoma tissues compared to adjacent normal tissues (P < 0.001). Low CYB561 expression was significantly associated with advanced FIGO stage (P < 0.05). Moreover, patients with low CYB561 expression exhibited significantly poorer overall survival (OS) and disease-free survival (DFS) (log-rank P < 0.001 for both).
CYB561 is up-regulated in endometrial carcinoma, and its high expression is associated with a more favorable prognosis, suggesting its potential role as a prognostic biomarker for endometrial cancer.